HOWL Werewolf Therapeutics, Inc.
Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The …
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 1 Penny Stock That Could Howl Its Way to the Top After a $150 Million Funding Boost A merger and a $150 million capital infusion is giving Werewolf's next chapter more firepower, but investors still face risks. | ||
 Little-Known HOWL Stock Skyrockets 100% on Biotech Merger News Werewolf Therapeutics stock explodes higher on a merger agreement with Ambros Therapeutics. But is there any further upside left in HOWL shares? | ||
Sector Update: Healthcare Stocks Advance in Afternoon Trading Healthcare stocks were higher Friday afternoon, with the NYSE Healthcare Index rising 1.4% and the S | ||
 Werewolf Therapeutics shares surge 120% after Ambros merger and $150 million financing Werewolf Therapeutics Inc (NASDAQ:HOWL) shares soared 120% in premarket trading on Friday after the biotechnology company agreed to merge with Ambros Therapeutics Inc alongside a $150 million private placement. The all-stock combination will create a company centred on the development of neridronate, Ambros Therapeutics’ late-stage drug candidate for Complex Regional Pain Syndrome Type 1 (CRPS-1). | ||
 JAZZ Q2 Earnings Miss, Sales Beat, Stock Jumps on Raised '26 View Jazz Pharmaceuticals tops Q2 sales estimates and raises its 2026 revenue outlook despite an EPS miss, as strong oncology and neuroscience demand lifts shares. | ||